Medical Policy: 01.01.20 
Original Effective Date: September 2012 
Reviewed: April 2016 
Revised: June 2014 


Benefit Application:

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.


Description:

Negative pressure wound therapy (NPWT) consists of the use of a negative pressure or suction device to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue and wound healing. The devices may also be used as an adjunct to surgical therapy or as an alternative to surgery in a debilitated patient.

 

Conventional NPWT using a powered negative pressure wound therapy system can be bulky and intrusive for patients who are ambulatory and active, disposable non-powered mechanical negative pressure wound therapy or single use non-electrically powered negative pressure wound therapy have been proposed for the treatment of small to medium sized, slow to heal wounds. The goal of these devices is to make it easier to use by both the clinicians and patients. Specifically, the device should be one that clinicians can take off the shelf like any other wound care dressing, it is quick and easy to apply, and the patients can wear under their clothes and will not impinge on normal activities. The idea was to make it practical and cost effective, allowing more patients to benefit from NPWT in the outpatient/home setting.

 

Disposable Non-Powered and Single Use Non-Electrically Powered NPWT Devices
SNaP® Wound Care System

The Smart Negative Pressure (SNaP)® Wound Care System (Spiracur, Sunnyvale, CA) is a disposable, ultraportable NPWT device that does not require an electrically-or-battery powered pump.  The SNaP System is a mechanically-powered NPWT system comprising spring technology that reduces air density within an enclosure in a controlled manner.  The specialized springs equilibrate even in the presence of exudate so that a constant controlled amount of negative pressure is delivered to the wound bed.  Because there is no electrical pump, operation of the SNaP System is completely silent, and it is small enough to be worn on a patient's leg, arm or belt and hidden underneath clothing. 

 

The (SNaP)® Wound Care System consists of three basic elements; the cartridge with activation/reset key, the hydrocolloid dressing layer, and the strap with attachment clip.

  • Cartridge with activation/reset key: Comes in three different pre-set pressure levels (-75mmHg, -100mmHg and -125mmHg). The cartridge has two functions: 1) it is a small canister that stores fluids removed from the wound (canister capacity of approximately 60mL of wound exudate) and 2) it generates the negative pressure or suction. The SNaP System also incorporates BioLock technology that isolyzes or gels the wound exudate that collects in the cartridge.  This helps to control potential contamination and odor. 
  • Hydrocolloid dressing layer with integrated nozzle and tubing and choice of foam or antimicrobial gauze wound interface layer: A proprietary hydrocolloid dressing provides protection to the often fragile peri-wound skin, improves dressing applications handling properties, and provides a robust seal around the wound for negative pressure delivery. The suction port and tubing (which can be cut to length) are fully integrated into the hydrocolloid dressing, simplifying the application process.

The hydrocolloid dressing is used over a wound filling material consisting of specialized SNaP Blue foam dressing or antimicrobial gauze dressing.

  • The Blue foam dressings allows for similar mechanical transduction of stress and strain to the wound bed as other foam wound interfaces. The bright blue color of the foam dressing also allows for easy visualization within the wound, helping to prevent retention of the foam at dressing changes. In general, the foam dressing is used when more robust granulation tissue formation is required or in deeper wounds.
  • The antimicrobial gauze dressing is used in more superficial wounds or in wounds at higher risk of infection

Treatment Indications

The SNaP System is indicated for the removal of small amounts of exudate from the following types of wounds:

  • Chronic wounds such as diabetic foot ulcers, venous ulcers and pressure ulcers.
  • Traumatic/acute wounds
  • Subacute and dehisced

  • Partial-thickness burns

  • Surgically-closed incisions

  • Flaps and grafts 

Contraindications   
The SNaP System should not be used over:

  • Actively infected wounds
  • Inadequately drained wounds
  • Necrotic tissue such as eschar or adherent slough
  • Exposed blood vessels, anastomotic sites, organs, tendons or nerves
  • Wounds containing malignancy
  • Fistulae
  • Untreated osteomyelitis
  • Actively bleeding wounds

It is recommended that the dressing be changed at least two times per week by the patient’s healthcare provider. The frequency of the dressing changes will depend on a number of factors (e.g. the level of exudate, bacterial load and rate of granulation tissue).

 

In 2011, Armstrong and colleagues reported results of a planned interim analysis of a randomized controlled trial (RCT) comparing the SNaP® device and the V.A.C.® (Negative pressure therapy Assisted Closure®) Therapy™ (Kinetic Concepts, Inc., San Antonia, TX) for the treatment of chronic lower extremity wounds.  The study randomized 132 patients with lower extremity venous or diabetic ulcers of varying size and present more than 30 days despite appropriate care. Dressings were changed per manufacturer direction, 2 times per week in the SNaP® group and 3 times per week in the V.A.C.® group. Patients were assessed for up to 16 weeks or until complete wound closure; 83 patients (63%) completed the study. Intention-to-treat analysis with the last observation carried forward showed non-inferiority in the primary outcome of wound size reduction at 4, 8, 12 and 16 weeks. When adjusted for differences in wound size at baseline,SNaP-treated subjects showed non-inferiority to the VAC-treated subjects at 4, 12, and 16 weeks. Kaplan-Meier analysis showed no significant difference in complete wound closure between the two groups. At the final follow up,  65.6% of the VAC group and 63.6% of the SNaP group had wound closure. Survey data indicated that dressing changes required less time, and the use of the SNaP® device interfered less with mobility and activity than the V.A.C.® device. This study is limited by the high loss to follow-up and the lack of comparison with standard treatment protocols.

 

A retrospective study with historical controls compared negative pressure wound therapy using the SNaP® device (n=28) with wound care protocols that included the use of Apligraf® (Novartis), Regranex® (Healthpoint Ltd.), and skin grafting (n=42) for treatment of lower extremity ulcers. Seven patients (25%) in the SNaP®-treated group could not tolerate the treatment and were discontinued from the study because of complications (allergic skin reaction, wound infection, bleeding after debridement preventing reapplication, worsening lower extremity edema, and the development of maceration severe enough to require discontinuation) and were considered treatment failures. Between-group estimates of time-to-wound healing by Kaplan-Meier analysis favored the SNaP® treatment group. The study is limited by the use of historical controls, the multiple modalities used in treatment of controls, and the large number of dropouts. The authors noted that patients in the SNaP®-treated group may have benefitted from being in an experimental environment, particularly because wounds in this group were seen twice per week compared to variable follow-up in the historical controls.

 

Other publications have described use of the SNaP® device in case series with small numbers of patients, fewer than 15 patients.

 

PICO™ Single Use Negative Pressure Wound Therapy
PICO™ Single Use Negative Pressure Wound Therapy (Smith and Nephew, St. Petersburg, FL) is a pocket sized disposable single use negative pressure wound therapy system. The PICO™ device consists of a small, portable pump with a lifespan of up to 7 days. The PICO™ pump generates an effective negative pressure of 80mmHg yet is small enough to fit discretely into a pocket. 

   

The PICO™ pump is connected to a specially designed dressing which: 1) maintains the negative pressure across the wound bed and 2) removes the exudate from the wound bed through absorbency and evaporation. In each carton there is one pump plus two AA lithium batteries and two separately packed dressings complete with fixation strips. This enables a dressing change to be carried out within the lifespan of the pump if this is clinically necessary.

 

PICO™ Single Use Negative Pressure Wound Therapy System is indicated for patients who would benefit from a suction device (negative pressure wound therapy) as it may promote wound healing via removal of low levels of exudates and infectious materials. Examples of appropriate wound types include: chronic wounds; acute wounds; traumatic wounds; subacute and dehisced wounds; partial thickness burns; ulcers (such as diabetic or pressure); flaps and grafts; closed surgical incisions.

 

In a prospective multicenter study, Hudson et al. (2013) assessed overall functionality and performance of the disposable PICO NPWT system including the ability of the system to manage exudate without a canister, concomitant delivery of NPWT and wound progress towards healing during the treatment phase. The study included 20 individuals. Sixteen had closed surgical wounds, two had traumatic wounds and two received meshed split thickness skin grafts. The mean study duration was 10.7 days (range: 5–14 days) and the mean dressing wear time per individual patient was 4.6 days (range: 2–11). A total of 55% of the wounds had closed by the end of the 14-day study or earlier, with 40% of wounds progressing to closure. Two wounds were clinically infected and a further wound had clinical signs of infection at recruitment. Two of these wounds were successfully skin grafted during the treatment period. One device-related adverse event observed small blister-like lesions around the wound associated with the removal of adhesive film fixation strips. This study is limited by small sample size and lack of a comparator.

 

V.A.C.Via™ Therapy System
V.A.C.Via™ Therapy  System (KCI, San Antonio, TX) is a portable single patient use negative pressure wound therapy device that offers 7 days of therapy. Provides dynamic pressure control and continuous negative pressure options of 75mmHg or 125mmHg.

 

The system is designed for moderate to lower-severity wounds and provides the same clinical efficacy as current V.A.C.® therapy products. The V.A.C.Via™ System creates an environment that promotes healing by: 1) maintaining a moist wound healing environment, 2) remove excess wound fluids and infectious material and 3) creating an environment that promotes perfusion and granulation tissue formation.

 

V.A.C.Via™ Therapy System is indicted for open wound types including: chronic, acute, traumatic, subacute and dehisced wounds, partial thickness burns, ulcers (such as diabetic, pressure or venous insufficiency), flaps and grafts.

 

When used on closed surgical incisions, it is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy.

 

In a retrospective study, Gabrielle et al. (2013) evaluated use of the disposable, single-patient-use NPWT system (SP-NPWT) V.A.C.Via™ Therapy over dermal regeneration template (DRT) and/or skin grafts. SP-NPWT was initiated over a DRT and/or skin graft in 33 patients with 41 graft procedures. Endpoints were recorded and compared to a historical control group of 25 patients with 28 grafts bolstered with traditional rental NPWT (V.A.C.). Mean age was less for the SP-NPWT group versus the control and there were significantly more patients with peripheral vascular disease (PVD) in the SP-NPWT group compared with the control (12 versus 0, respectively). A greater number of acute wounds were present in the SP-NPWT group versus the control (26 versus 10, respectively). All other patient demographics and wound characteristics were similar. Mean follow-up time was 6.4 months for the SP-NPWT group and 12.7 months for the control group. Primary endpoint was time to hospital discharge, duration of SP-NPWT and graft take rate were collected and compared to a historical control group of patients who received traditional rental NPWT over dermal regeneration template (DRT) and/or skin grafts. Average length of inpatient hospital stay was 0 days for the SP-NPWT group and six days for the control group. The average duration of SP-NPWT post-DRT or skin graft was 5.6 days and 7.0 days for the control. This study is limited by small sample size, lack of a comparator and observer bias in estimating graft take. The authors reported that considerably more controlled research is necessary to measure efficacy of SP-NPWT in the adjunctive management of various wound types.

 

ciSNaP® Closed Incision System
ciSNaP® Closed Incision System (Spiracur, Sunnyvale, CA) is a single use portable, non-powered, disposable negative pressure wound therapy system that is intended for wound management through the removal of small amounts of exudate from surgical incisions that continue to drain following sutured or stapled closure.

  

The ciSNaP® Closed Incision System has a sterile cartridge that provides negative pressure therapy which increases blood flow to improve wound healing. There is proprietary spring mechanism that generates consistent, even levels of pressure. A visual indicator displays when cartridge is full or discharged. Silicone wings help to approximate wound edges, reducing potential risk of dehiscence and minimizing tension on staples and sutures which is customizable in length to fit a wide range of incisions.  A proprietary hydrocolloid dressing and antimicrobial gauze offer a protective barrier to minimize potential for infection and eliminate the need for dressing changes. A soft strap enables the device to be conveniently worn on the extremity or belt.

 

The use of the ciSNaP® Closed Incision System over surgical incisions may results in:

  • Lowered rate of infection
  • Reduced risk of dehiscence
  • Improved cosmesis
  • Fewer complications and associated costs

Summary

Based on review of the medical literature, the RCTs have small numbers of patients using disposable non-powered mechanical or single use non-electrically powered negative pressure wound therapy systems are insufficient to draw conclusions about its impact on net health outcome, both for the device itself and in comparison with current care. Well - designed comparative studies with larger number of patients are needed.  Results from larger RCTs are expected.  The evidence is insufficient to determine the safety, efficacy and effects on health outcomes at this time and therefore these devices are considered investigational for all indications.

 

Regulatory Status
Numerous disposable negative pressure wound therapy systems have received Class II clearance by the FDA through the 510(k) process.
 
The SNaP® Wound Care System (Spiracur, Sunnyvale, CA) is a Class II device requiring notification to market but not having U.S. Food and Drug Administration (FDA) premarket approval. It received 510(k) marketing clearance from the FDA in 2009 (K081406) and is indicated for the removal of small amounts of exudate from chronic, acute, traumatic, subacute and dehisced wounds, partial thickness burns, ulcers (such as diabetic or pressure), surgically closed incisions, flaps and grafts.

 

The FDA granted 510(k) Class II clearance for the PICO™ Single Use Negative Pressure Wound Therapy System (Smith and Nephew, St Petersburg, FL) on December 15, 2011. PICO was cleared as substantially equivalent to predicate devices Renasys Go (Smith & Nephew), NPD 1000 NPWT System (Kalypto Medical, Hastings, MN), and Prevena Incision Management System (KCI, San Antonio, TX). The intended use, indications and instructions for use for the subject and predicate devices are similar. According to the 510(k) clearance document, “the PICO is indicated for patients who would benefit from a suction device (negative pressure wound therapy) as it may promote wound healing via removal of low to moderate levels of exudate and infectious materials. The PICO [single-use NPWT] System is suitable for use in both a hospital and homecare setting. Examples of appropriate wound types include: chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts, closed surgical incisions.”

 

The FDA granted 510(k) Class II clearance for the V.A.C.Via™ Negative Pressure Wound Therapy System, (KCI, San Antonio, TX) on March 10, 2010. Equivalence is claimed to the KCI Acti V.A.C.™ Therapy System (KCI, San Antonio, TX). The intended use for the device states, “V.A.C.Via™ Negative Pressure Wound Therapy System is an integrated wound management system for use in acute, extended and home care settings. It is intended to create an environment that promotes wound healing by secondary or tertiary (delayed primary) intention by preparing the wound bed for closure, reducing edema, promoting granulation tissue formation and perfusion, and by removing exudates and infectious material. It is indicated for patients with chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure or venous insufficiency), flaps and grafts.”

 

The FDA granted 510(K) Class II clearance for the ciSNaP® Closed Incision System (Spiracur, Sunnyvale, CA) on February 25, 2014. This is a non-powered suction apparatus device intended for negative pressure wound therapy for patients who would benefit from wound management via the application of negative pressure, particularly as the device promotes wound healing through the removal of small amounts of exudate from surgical incisions that continue to drain following sutured or stapled closure.


Prior Approval:

 

 

Not applicable


Policy:

The use of non-powered mechanical negative pressure wound care systems or single use non-electrically powered negative pressure wound therap systemsy, including but not limited to the following, is considered investigational for the treatment of all indications:

  • SNaP® Wound Care System
  • PICO™ Single Use Negative Pressure Wound Therapy
  • V.A.C.Via™ Therapy System
  • ciSNaP® Closed Incision System  

Based on review of the medical literature, the RCTs have small numbers of patients using the disposable non-powered mechanical or single use non-electrically powered negative pressure wound therapy systems are insufficient to draw conclusions about its impact on net health outcome, both for the device itself and in comparison with current care.  Well - designed comparative studies with larger number of patients are needed. Results from larger RCTs are expected.  The evidence is insufficient to determine the safety, efficacy and effects on health outcomes at this time.  Therefore, the use of disposable non-powered mechanical or single use non-electrically powered negative pressure wound therapy systems for any indication is considered investigational.



Procedure Codes and Billing Guidelines:

  • To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or diagnosis codes.
  • A9272  Wound suction, disposable, includes dressing, all accessories and components, any type, each.
  • 97607   Negative pressure wound therapy, (eg, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters
  • 97608   Negative pressure wound therapy, (eg, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters 

Selected References:

  • Lerman B, Oldenbrook L, Ryu J et al. The SNaP Wound Care System, a case series using a novel ultraportable negative pressure wound therapy device for the treatment of diabetic lower extremity wounds. J Diabetes Sci Technol 2010; 4(4):825-30.
  • Landsman A. Analysis of the SNaP Wound Care System, a negative pressure wound device for treatment of diabetic lower extremity wounds. J Diabetes Sci Technol 2010; 4(4):831-2.
  • Armstrong DG, Marston WA, Reyzelman AM et al. Comparison of negative pressure wound therapy with an ultraportable mechanically powered device vs. traditional electrically powered device for the treatment of chronic lower extremity ulcers: a multicenter randomized-controlled trial. Wound Repair Regen 2011;19(2):173-80.
  • Lerman B, Oldenbrook L, Eichstadt SL, et al. Evaluation of chronic wound treatment with the SNaP wound care system versus modern dressing protocols. Plast Reconstr Surg 2010; 126(4):1253-61.
  • Fong KD, Hu D Eichstadt S et al. Initial clinical experience using a novel ultraportable negative pressure wound therapy device. Wounds 2010; 22(9):230-6.
  • Hutton DW, Sheehan P. Comparative effectiveness of the SNaP&trade Wound Care System. Int Wound J. 2011 Apr;8(2):196-205. doi: 10.1111/j.1742-481X.2011.00775.x. Epub  2011 Mar 8.
  • Fong KD, Marston W. Advances in Wound Care. February 2012, 1(1): 41-43.  SNaP® Wound Care System: Ultraportable Mechanically Powered Negative Pressure Wound Therapy. Available at: http://ncbi.nlm.nih.gov
  • ECRIExternal Site Hotline Response. Managing Acute and Chronic Wounds Using Negative Pressure Wound Therapy Systems from Smith & Nephew, Inc. March 2013.
  • ECRIExternal Site Product Brief. PICO Single Use System (Smith & Nephew, Inc.) for Delivering Negative Pressure Wound Therapy. May 2012.
  • UpToDateExternal Site Negative Pressure Wound Therapy. Mark Gestring, M.D.. Topic last updated January 13, 2014.
  • UpToDateExternal Site Spiracur.com. SNaP® Wound Care System and ciSNaP® Closed Incision System.
  • Smith & NephewExternal Site PICO™ Single Use Negative Pressure Wound Therapy System.
  • KCIExternal Site V.A.C. Via™ Negative Pressure Wound Therapy System.
  • FDA. U.S. Food and Drug AdministrationExternal Site 510(k) Summary  V.A.C. Via™ Negative Pressure Wound Therapy System November 15, 2013 & March 10, 2010.. Accessed June 19, 2014.
  • FDA. U.S. Food and Drug AdministrationExternal Site 510(k) Summary PICO™ Single Use Negative Pressure Wound Therapy System December 15, 2011. A. Accessed June 19, 2014
  • FDA. U.S. Food and Drug AdministrationExternal Site 510(k) Summary ciSNaP® Closed Incision System February 25, 2014. AAccessed June 19, 2014
  • FDA. U.S. Food and Drug AdministrationExternal Site 510(k) Summary SNaP® Wound Care System. Accessed June 19, 2014
  • Donald A. Hudson, Kevin G. Adams, et. al. Simplified Negative Pressure Wound Therapy: Clinical Evaluation of an ultraportable, no canister systemExternal Site International Wound Journal ISSN 1742-4801, May 7, 2013
  • Karen Shum, DPM and Kazu Suzuki, DPM, CWS, Emerging Insights on Negative Pressure Wound Therapy. Podiatry TodayExternal Site August 2013.
  • ECRIExternal Site Product Brief, SNaP Wound Care System (Spiracur, Inc) for Delivering Negative Pressure Wound Therapy, September 2014.
  • Fong K, Marston W. SNaP Wound Care System: Ultraportable Mechanically Powered Negative Pressure Wound Therapy. Advances in Wound Care, Volume 1, Number 1 2012
  • Rhee SM, Valle MF, Wilson LM, et al. Negative Pressure Wound Therapy Technologies For Chronic Wound Care in the Home Setting. Evidence Report/Technology Assessment. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-201-200007-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 15, 2014..
  • Rhee SM, Valle MF, Wilson LM, et al. Negative pressure wound therapy technologies for chronic wound care in the home setting: A systematic review. Wound Repair Regen. Jul 2015;23(4):506-517. PMID 25845268
  • Ubbink DT, Westerbos SJ, Evans D, et al. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev. 2008(3):CD001898. PMID 18646080
  • Dumville JC, Webster J, Evans D, et al. Negative pressure wound therapy for treating pressure ulcers. Cochrane Database Syst Rev. 2015;5:CD011334. PMID 25992684
  • Dumville JC, Land L, Evans D, et al. Negative pressure wound therapy for treating leg ulcers. CochraneDatabase Syst Rev. 2015;7:CD011354. PMID 26171910
  • Armstrong DG, Marston WA, Reyzelman AM, et al. Comparison of negative pressure wound therapy with an ultraportable mechanically powered device vs. traditional electrically powered device for the treatment of chronic lower extremity ulcers: a multicenter randomized-controlled trial. Wound Repair Regen. Mar-Apr 2011;19(2):173-180. PMID 21362084
  • Armstrong DG, Marston WA, Reyzelman AM, et al. Comparative effectiveness of mechanically and electrically powered negative pressure wound therapy devices: a multicenter randomized controlled trial. Wound Repair Regen. May-Jun 2012;20(3):332-341. PMID 22564228
  • Marston WA, Armstrong DG, Reyzelman AM, et al. A Multicenter Randomized Controlled Trial Comparing Treatment of Venous Leg Ulcers Using Mechanically Versus Electrically Powered Negative Pressure Wound Therapy. Adv Wound Care (New Rochelle). Feb 1 2015;4(2):75-82. PMID 25713749
  • Lerman B, Oldenbrook L, Eichstadt SL, et al. Evaluation of chronic wound treatment with the SNaP wound care system versus modern dressing protocols. Plast Reconstr Surg. Oct 2010;126(4):1253-1261. PMID 20885246
  • Lipsky BA, Berendt AR, Cornia PB, et al. Infectious Diseases Society of America (IDSA), Clinical practice guideline for the diagnosis and treatment of diabetic foot infectionsExternal Site Clinical Infectious Diseases 2012;54(12):132–173.
  • National Institute for Health and Clinical Excellence (NICE). Negative Pressure Wound Therapy for the Open AbdomenExternal Site IPG 322. 2009. 
  • National Institute for Health and Care Excellence (NICE). NICE Clinical Guideline NG19. Diabetic Foot Problems: Prevention and ManagementExternal Site. 2015.
  • Royal College of Nursing and National Institute for Health and Clinical Excellence. The Management of Pressure Ulcers in Primary and Secondary CareExternal Site Clinical Guidance 29. 2005
  • American Society of Plastic SurgeonsExternal Site (ASPS). Evidence-based Clinical Practice Guideline: Chronic Wounds of the Lower Extremity. 2007
  • American College of Foot and Ankle Surgeons (ACFAS). Diabetic Foot Disorders: A Clinical Practice GuidelineExternal Site 2006
  • Birke-Sorensen H, Malmsjo M, Rome P., et. al. Evidence based recommendations for negative pressure wound therapy: treatment variables (pressure levels, wound filler and contact layer) – steps toward an international consensus. J Plast Reconstr Aesthet Surg 2011 Sep;64 Suppl: S1-16. PMID 21868296
  • Lerman B, Oldenbrook L, Eichstadt SL, et. al. Evaluation of chronic wound treatment with the SNaP wound care system versus modern dressing protocols. Plast Reconstr Surg 2010 Oct;126(4):1253-61. PMID 20885246

Policy History:

  • April 2016 - Annual Review, Policy Renewed
  • May 2015 - Annual Review, Policy Renewed
  • June 2014 - Annual Review, Policy Revised
  • August 2013 - Annual Review, Policy Renewed
  • September 2012 - New Policy

Wellmark medical policies address the complex issue of technology assessment of new and emerging treatments, devices, drugs, etc.   They are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. Wellmark medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Wellmark does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Wellmark or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies may be updated and therefore are subject to change without notice.

*Current Procedural Terminology © 2012 American Medical Association. All Rights Reserved.